Hemispherx Biopharma (HEB) Release: A Clinical Update On The Search For A Universal Flu Vaccine: Presentation In Washington, DC On January 30, 2014 In Conjunction With The American Society of Microbiology Biodefense Conference
1/28/2014 9:08:19 AM
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott Wardman Park Hotel, Washington DC. The University of Alabama and Hemispherx's poster presentation is entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen®), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" and will be provided in poster format by Dr. E. Turner Overton, an infectious disease expert at UAB, in the afternoon of January 29, 2014. The presentation will be available on the Hemispherx website. Ampligen® (rintatolimod) is an experimental therapeutic.
Help employers find you! Check out all the jobs and post your resume.
comments powered by